ADVFN Logo ADVFN
市場データ
ニュース
投資ツール
市場
発見

Hot Features

Follow Feed

フォローフィードコミュニティでトレーダーや投資家とつながりましょう.

ライブオプションフロー

包括的なオプション データを調査し、オプション フローで高度なフィルターを使用します.

モニター

ターミナル モニターで株式と資産のウォッチリストを整理および監視します
サインイン Premium Iconプレミアム Help Menu
Bitcoin
70,734.11
-1.00%
S&P 500
5,305.72
-0.05%
Dow Jones
39,831.73
0.06%
US Dollar vs Yen
156.1605
-0.14%
Brent Oil
82.635
-1.07%
Registration Strip Icon for alerts 登録してリアルタイムのアラート、カスタムポートフォリオ、市場の動きを入手してください。
登録
  1. ホーム
  2. 投資
  3. 株式
  4. アメリカ
  5. NASDAQ
  6. Celldex Therapeutics Inc (CLDX)

  7. Celldex Therapeutics Inc (CLDX) ニュース

CLDX

Celldex Therapeutics (CLDX)

Celldex Therapeutics Inc
から:
次の項目別のソート:
 Showing the most relevant articles for your search:NASDAQ:CLDX
日付受信時刻ニュースソース見出しコード企業名
2024/05/1521 : 01GlobeNewswire Inc.Celldex Announces First Patient Dosed in Phase 2 Study of Barzolvolimab in Prurigo NodularisNASDAQ:CLDXCelldex Therapeutics Inc
2024/05/0705 : 07Edgar (US Regulatory)Form 10-Q - Quarterly report [Sections 13 or 15(d)]NASDAQ:CLDXCelldex Therapeutics Inc
2024/05/0705 : 01Edgar (US Regulatory)Form 8-K - Current reportNASDAQ:CLDXCelldex Therapeutics Inc
2024/05/0705 : 01GlobeNewswire Inc.Celldex Reports First Quarter 2024 Financial Results and Provides Corporate UpdateNASDAQ:CLDXCelldex Therapeutics Inc
2024/04/1721 : 01GlobeNewswire Inc.Celldex Announces Completion of Enrollment in Phase 2 Study of Barzolvolimab in Patients with Chronic Inducible UrticariaNASDAQ:CLDXCelldex Therapeutics Inc
2024/03/0821 : 00GlobeNewswire Inc.Celldex Therapeutics to Participate in the Leerink Partners Global Biopharma ConferenceNASDAQ:CLDXCelldex Therapeutics Inc
2024/03/0600 : 30GlobeNewswire Inc.Celldex Therapeutics to Present at TD Cowen’s 44th Annual Health Care ConferenceNASDAQ:CLDXCelldex Therapeutics Inc
2024/03/0600 : 10GlobeNewswire Inc.Celldex Therapeutics Announces Closing of Public Offering of Common Stock and Full Exercise of Underwriters’ Option to Purchase Additional SharesNASDAQ:CLDXCelldex Therapeutics Inc
2024/03/0206 : 10Edgar (US Regulatory)Form 8-K - Current reportNASDAQ:CLDXCelldex Therapeutics Inc
2024/03/0206 : 09Edgar (US Regulatory)Form 424B5 - Prospectus [Rule 424(b)(5)]NASDAQ:CLDXCelldex Therapeutics Inc
2024/03/0111 : 14GlobeNewswire Inc.Celldex Therapeutics Announces Pricing of Upsized $400 Million Public Offering of Common StockNASDAQ:CLDXCelldex Therapeutics Inc
2024/02/2906 : 10Edgar (US Regulatory)Form 424B5 - Prospectus [Rule 424(b)(5)]NASDAQ:CLDXCelldex Therapeutics Inc
2024/02/2906 : 01GlobeNewswire Inc.Celldex Therapeutics Announces Proposed Public Offering of Common StockNASDAQ:CLDXCelldex Therapeutics Inc
2024/02/2622 : 18Edgar (US Regulatory)Form 424B5 - Prospectus [Rule 424(b)(5)]NASDAQ:CLDXCelldex Therapeutics Inc
2024/02/2621 : 05Edgar (US Regulatory)Form 10-K - Annual report [Section 13 and 15(d), not S-K Item 405]NASDAQ:CLDXCelldex Therapeutics Inc
2024/02/2621 : 01Edgar (US Regulatory)Form 8-K - Current reportNASDAQ:CLDXCelldex Therapeutics Inc
2024/02/2621 : 01GlobeNewswire Inc.Celldex Reports Fourth Quarter and Year End 2023 Financial Results and Provides Corporate UpdateNASDAQ:CLDXCelldex Therapeutics Inc
2024/02/2504 : 05GlobeNewswire Inc.Celldex Therapeutics Presents Positive 12 Week Results from Barzolvolimab Phase 2 Study in Chronic Spontaneous UrticariaNASDAQ:CLDXCelldex Therapeutics Inc
2024/02/1606 : 05Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:CLDXCelldex Therapeutics Inc
2024/02/1506 : 17Edgar (US Regulatory)Form SC 13G/A - Statement of acquisition of beneficial ownership by individuals: [Amend]NASDAQ:CLDXCelldex Therapeutics Inc
2024/02/1502 : 52Edgar (US Regulatory)Form SC 13G - Statement of acquisition of beneficial ownership by individualsNASDAQ:CLDXCelldex Therapeutics Inc
2024/02/1501 : 48Edgar (US Regulatory)Form SC 13G - Statement of acquisition of beneficial ownership by individualsNASDAQ:CLDXCelldex Therapeutics Inc
2024/02/1421 : 38Edgar (US Regulatory)Form SC 13G/A - Statement of acquisition of beneficial ownership by individuals: [Amend]NASDAQ:CLDXCelldex Therapeutics Inc
2024/02/1323 : 41Edgar (US Regulatory)Form SC 13G - Statement of acquisition of beneficial ownership by individualsNASDAQ:CLDXCelldex Therapeutics Inc
2024/02/0900 : 11Edgar (US Regulatory)Form SC 13G/A - Statement of acquisition of beneficial ownership by individuals: [Amend]NASDAQ:CLDXCelldex Therapeutics Inc
2024/02/0706 : 01GlobeNewswire Inc.Celldex to Participate in the Guggenheim Healthcare Talks 6th Annual Biotechnology ConferenceNASDAQ:CLDXCelldex Therapeutics Inc
2024/02/0522 : 01GlobeNewswire Inc.Celldex Announces Upcoming Presentation of Barzolvolimab Phase 2 Results in Chronic Spontaneous Urticaria at AAAAI 2024NASDAQ:CLDXCelldex Therapeutics Inc
2024/01/0506 : 05Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:CLDXCelldex Therapeutics Inc
2023/11/2806 : 15GlobeNewswire Inc.Celldex Therapeutics to Present at 6th Annual Evercore ISI HealthCONx ConferenceNASDAQ:CLDXCelldex Therapeutics Inc
2023/11/2106 : 15Edgar (US Regulatory)Form SC 13G - Statement of acquisition of beneficial ownership by individualsNASDAQ:CLDXCelldex Therapeutics Inc
 Showing the most relevant articles for your search:NASDAQ:CLDX

最近閲覧した銘柄

NASDAQ
AAPL
Apple
NYSE
CVX
Chevron
USOTC
BNPQY
BNP Paribas (QX)
NASDAQ
AMZN
Amazon.com
AMEX
XLV
Health Care Select Sector
FX
USDJPY
US Dollar vs Yen
CCOM
US500
US 500
USOTC
RHHBY
Roche (QX)
NYSE
XOM
Exxon Mobil
SPI
SP500
S&P 500
NYSE
NKE
Nike
NASDAQ
GOOGL
Alphabet
CCOM
SILVER
SILVER
COIN
BTCUSD
Bitcoin
USOTC
DTEGY
Deutsche Telekom (QX)
Delayed Upgrade Clock
ADVFN Logo

日本
会社情報
ビジネス
人気
アプリを入手

顧客サポート: +44 (0) 203 8794 460 | support@advfn.com

ADVFNのサービスをご利用いただくには、利用規約

© 2024 ADVFN PLC - 全著作権所有